Article Text

G433 Predictors of insulin resistance and the effect of metformin treatment in obese paediatric patients
  1. H Gallen1,
  2. I Banerjee2,
  3. PE Clayton2,
  4. S Ehtisham2,
  5. R Padidela2,
  6. L Patel2,
  7. M Skae2
  1. 1Manchester Medical School, The University of Manchester, Manchester, UK
  2. 2Department of Paediatric Endocrinology, Royal Manchester Children’s Hospital, Manchester, UK


Aims Paediatric obesity is a growing concern for the health service. There is currently no consensus for routine screening of metabolic profiles and medical treatment in obese paediatric patients. We aimed to determine medium-term outcomes of Metformin treatment on BMI, glucose and insulin levels in obese paediatric patients.

Methods In a retrospective review, data were collected from obese paediatric patients treated with Metformin for insulin resistance between October-09 and October-14. Demographic data was collected from these patients including presence of acanthosis nigricans (AN) and family history of T2DM. Changes in BMI SDS, glucose and insulin were analysed. Paired sample T-tests were used to compare pre and post treatment results (treatment washout period of 1 month).

Results 70 patients were treated with metformin (50=female) (35=British White, 18=Pakistani) at a mean age of 12.7 (6.1–17.2) years. Mean BMI 35.2 (24.2–48.5 kg/m2) and BMI SDS 3.4 (2.2–4.7). All the patients had insulin resistance at start of treatment. 21 (30%) of these had both family history of T2DM and AN. An additional 22 patients had AN only (total with AN=43, 49%). Those with AN had significantly higher basal insulin levels (p < 0.05) than those without. Metformin was associated with reduced BMI z-score at 6–12 months (-0.1 SDS, p < 0.05) and 18–24 months (-0.2 SDS, p < 0.05). Reduction in fasting and postprandial glucose levels were (-0.1 mmol/L, p = 0.17) and (-0.5 mmol/L, p = 0.17) respectively, with a significant reduction in postprandial glucose levels in those patients with impaired glucose tolerance (n = 13) (-1.9 mmol/L, p < 0.05). Metformin was associated with a reduction in fasting insulin (-3.0 mU/L,p = 0.44), and significantly reduced 2 h insulin (-118.0 mU/L, p < 0.05) after treatment for 12–18 months.

Conclusions Acanthosis nigricans is a good clinical indicator for the presence of insulin resistance. Metformin treatment is significantly associated with reduction in BMI z-score from 6 months and reduced postprandial insulin levels after treatment. It should be considered as a treatment modality in normoglycaemic obese paediatric patients for weight stabilisation and improvement of insulin resistance, which may have longer term implications on metabolic health.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.